ATE538100T1 - Aminotetrahydroindazoloessigsäuren - Google Patents

Aminotetrahydroindazoloessigsäuren

Info

Publication number
ATE538100T1
ATE538100T1 AT09780159T AT09780159T ATE538100T1 AT E538100 T1 ATE538100 T1 AT E538100T1 AT 09780159 T AT09780159 T AT 09780159T AT 09780159 T AT09780159 T AT 09780159T AT E538100 T1 ATE538100 T1 AT E538100T1
Authority
AT
Austria
Prior art keywords
compounds
formula
aminotetrahydroindazoloacetic
acids
receptor
Prior art date
Application number
AT09780159T
Other languages
English (en)
Inventor
Li Chen
Fariborz Firooznia
Paul Gillespie
Yun He
Tai-An Lin
Sung-Sau So
Hongying Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE538100T1 publication Critical patent/ATE538100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT09780159T 2008-07-15 2009-07-06 Aminotetrahydroindazoloessigsäuren ATE538100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8070308P 2008-07-15 2008-07-15
PCT/EP2009/058468 WO2010006939A1 (en) 2008-07-15 2009-07-06 Aminotetrahydroindazoloacetic acids

Publications (1)

Publication Number Publication Date
ATE538100T1 true ATE538100T1 (de) 2012-01-15

Family

ID=41078142

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09780159T ATE538100T1 (de) 2008-07-15 2009-07-06 Aminotetrahydroindazoloessigsäuren

Country Status (8)

Country Link
US (2) US8124641B2 (de)
EP (1) EP2307382B1 (de)
JP (1) JP5394487B2 (de)
CN (1) CN102099342B (de)
AT (1) ATE538100T1 (de)
CA (1) CA2728311A1 (de)
ES (1) ES2378755T3 (de)
WO (1) WO2010006939A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730390A1 (en) * 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
PE20110703A1 (es) * 2008-11-17 2011-10-13 Hoffmann La Roche Acidos naftilaceticos
JP5373104B2 (ja) * 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
BRPI0921254A2 (pt) * 2008-11-17 2018-10-23 Hoffmann La Roche acidos naftilacéticos
PE20121519A1 (es) * 2010-01-27 2012-12-02 Boehringer Ingelheim Int Compuestos de pirazol como antagonistas de crth2
PL2558447T3 (pl) 2010-03-22 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
FR2974576B1 (fr) * 2011-04-29 2013-07-19 Sanofi Aventis Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US9000044B2 (en) 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
MX379014B (es) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd Formas cristalinas.
IT202100003794A1 (it) * 2021-02-18 2022-08-18 Fondazione St Italiano Tecnologia Metodo per la preparazione di derivati del pirazolo come modulatori della proteina cftr

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE3623941A1 (de) * 1986-07-16 1988-01-28 Bayer Ag Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
EP0405602A1 (de) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Zinkderivate von antientzündlichen Arzneimitteln mit verbesserter therapeutischer Aktivität
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP2562405B2 (ja) 1993-04-06 1996-12-11 花王株式会社 ケラチン繊維処理剤組成物
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US7393852B2 (en) * 2003-06-20 2008-07-01 Amgen Inc. Piperazine derivatives and methods of use
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR20070045153A (ko) * 2004-05-29 2007-05-02 7티엠 파마 에이/에스 의약용 씨알티에이치2 수용체 리간드
CN101124207A (zh) 2004-09-21 2008-02-13 阿特西斯公司 显示出crth2受体拮抗作用的苯并咪唑乙酸类和其用途
WO2006036664A1 (en) * 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
ATE409179T1 (de) * 2004-12-21 2008-10-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
EP1861372A1 (de) 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2-rezeptor-agonisten zur behandlung von entzündungskrankheiten
RU2405770C2 (ru) * 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
SG179472A1 (en) * 2007-03-27 2012-04-27 Shionogi & Co Method for producing n-phenyl-n'-phenylsulfonyl piperazine derivative
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
CA2730390A1 (en) * 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
JP5302401B2 (ja) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー モノアリールアミノテトラリン
JP5302398B2 (ja) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー 置換アミノテトラリン
JP5373104B2 (ja) 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
PE20110703A1 (es) 2008-11-17 2011-10-13 Hoffmann La Roche Acidos naftilaceticos

Also Published As

Publication number Publication date
CN102099342B (zh) 2013-07-10
ES2378755T3 (es) 2012-04-17
EP2307382B1 (de) 2011-12-21
CN102099342A (zh) 2011-06-15
US8268870B2 (en) 2012-09-18
JP2011528002A (ja) 2011-11-10
EP2307382A1 (de) 2011-04-13
US20120095053A1 (en) 2012-04-19
JP5394487B2 (ja) 2014-01-22
US8124641B2 (en) 2012-02-28
CA2728311A1 (en) 2010-01-21
US20100016368A1 (en) 2010-01-21
WO2010006939A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
WO2010018109A3 (en) Substituted aminotetralines
WO2010018112A3 (en) Monoaryl aminotetralines
WO2010018113A3 (en) Bi-aryl aminotetralines
MX350862B (es) Acidos de piperidinil naftilacetico.
EA201390934A1 (ru) Композиции и способы модулирования fxr
MY157429A (en) Trpm8 antagonists and their use in treatments
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
TN2011000310A1 (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
EA201690035A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
BR112014001801A2 (pt) indazóis
CA2818187C (en) Bromodomain inhibitors and uses thereof
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
EA201071320A1 (ru) Активаторы глюкокиназы
EA023861B3 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
IN2014KN01075A (de)
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.